← Back

Biolevate

Paris, France

series-a$34.4M raisedFreshly fundedBiotechAI InfrastructureDigital Health

Total Raised

$34.4M

Stage

series-a

Location

Paris, France

Founded

2024

Team size

11-50

Links

About Biolevate

Paris-based life sciences AI company providing an enterprise agentic AI platform for automating scientific and regulatory workflows in drug development.

What sets it apart

It combines scientific evidence, regulatory knowledge, company context, and governed AI agents to automate regulated work with auditability and human oversight.

Sectors

BiotechAI InfrastructureDigital HealthEnterprise SoftwareDrug Discovery

Business

ModelSaaS

CustomerLife sciences organizations, including pharma and biotech teams handling scientific, regulatory, and operational workflows

Notable

  • Raised €30 million Series A on 2026-09-22
  • Round co-led by RAISE France and Orange Ventures
  • Previously raised a €6 million seed round in November 2024
  • Opened a Boston office for U.S. expansion

Funding rounds

series-a$34.4M

22 Sept 2026

Led by RAISE France, Orange Ventures

With MSD Global Health Innovation Fund, Station F, EQT Ventures

Source ↗

Explore the market

FAQ

What does Biolevate do?

Paris-based life sciences AI company providing an enterprise agentic AI platform for automating scientific and regulatory workflows in drug development.

Where is Biolevate based?

Biolevate is based in Paris, France, founded in 2024.

How much has Biolevate raised?

Biolevate has raised $34.4M in tracked funding and is currently at the series-a stage.

Who has invested in Biolevate?

Investors in Biolevate include RAISE France, Orange Ventures, MSD Global Health Innovation Fund, Station F and EQT Ventures.